Avoro Capital Advisors Reduces Its Stake in RNAM ($RNAM)

Avoro Capital Advisors has completely sold out its position in RNAM, according to its latest 13F filing with the SEC. The fund cut 5.46 million shares, bringing its holdings to zero. This move was reported as of the filing date, May 15, 2026.

What Changed in Avoro Capital Advisors's RNAM Position

Avoro Capital Advisors eliminated its entire stake in RNAM, which previously stood at 5.46 million shares. This reduction represents a 100% decrease in its holdings, as the fund no longer holds any shares in the company.

Other Institutional Activity in RNAM

Other institutional investors have also adjusted their positions in RNAM. CORSICANA & CO. increased its holdings by 8,000 shares, ending with 8,000 shares valued at approximately $236,160. In contrast, Z3 CAPITAL PARTNERS, LLC, ROCKEFELLER CAPITAL MANAGEMENT L.P., and TD CAPITAL MANAGEMENT LLC all exited their positions completely, each reducing their holdings to zero. BLUEFIN CAPITAL MANAGEMENT, LLC also sold out its stake, cutting 10,000 shares.

Insider Buying and Selling at RNAM

Insider activity at RNAM has been notable. On February 27, 2026, several key executives sold shares. Chief Scientific Officer Michael Flanagan sold 397,500 shares, while President and CEO Sarah Boyce offloaded 474,861 shares. Other insiders, including Chief Legal Officer John Moriarty and Edward Kaye, MD, also sold significant numbers of shares.

Bottom Line

Avoro Capital Advisors's decision to sell its entire stake in RNAM is a significant move that investors will watch closely. This 13F filing, while backward-looking, provides insight into the fund's past investment strategy. As always, these filings reflect only the holdings at the end of the reporting period and do not necessarily indicate current positions.